Correction: Cross Keys Capital Advises New Jersey Cancer Care, PA, in Its Partnership with Regional Cancer Care Associates
August 23, 2024 08:00 ET
|
Cross Keys Capital, LLC.
Fort Lauderdale, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Cross Keys Capital, LLC, a leading independent investment banking firm providing M&A advisory services to physician group practices and...
SciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board
August 22, 2024 08:12 ET
|
SciSparc Ltd
Professor Peled is the Director of the Oncology Department at the Shaare Zedek Medical Center, Jerusalem, Israel, and the head of the Global Multidisciplinary Practice Standards Committee (GMPSC) of...
Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research
August 22, 2024 05:00 ET
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research
AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
August 20, 2024 08:30 ET
|
AIM ImmunoTech Inc.
Data demonstrate compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through Ampligen Additional commentary published discussing the potential of Ampligen and...
Cumulus Oncology and leadXpro Achieve Critical Milestone in GPR68 Drug Discovery Project
August 20, 2024 03:00 ET
|
Cumulus Oncology
EDINBURGH, Scotland and VILLIGEN, Switzerland, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Cumulus Oncology, Europe’s first oncology-focused biotech creation company, announces that, in partnership with its...
AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 16, 2024 07:00 ET
|
AIM ImmunoTech Inc.
– Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications – Company to host conference call and webcast today, August...
CORRECTION – Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares
August 15, 2024 12:17 ET
|
Tevogen Bio Inc
Tevogen Bio Reports Second Quarter 2024 Financial Results
Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares
August 15, 2024 09:00 ET
|
Tevogen Bio Inc
Tevogen Bio Reports Second Quarter 2024 Financial Results
TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
August 15, 2024 07:00 ET
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
CV6 Therapeutics Announces Initiation of Patient Dosing in Phase 1a Clinical Trial Evaluating the Investigational First-In-Class, Specific dUTPase Inhibitor CV6-168
August 15, 2024 04:00 ET
|
CV6 Therapeutics
– Study will assess the safety, pharmacokinetic and pharmacodynamic profiles and anti-tumor activity for CV6-168 in the treatment of multiple solid cancers, including colon, gastric, breast, ovarian,...